HARVARD BIOSCIENCE INC

For the period ended Mar 31, 2025. Filed May 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

HBIO$9.26+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders' Equity

HARVARD BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited, in thousands)

Accumulated
Number · Additional · Other · Total
	of Shares	Common	Paid-in	Accumulated	Comprehensive	Stockholders’
	Issued	Stock	Capital	Deficit	Loss	Equity
Balance at December 31, 2024	44,074	$441	$236,579	$(158,010)	$(15,670)	$63,340
Vesting of restricted stock units	247	1	-	-	-	1
Shares withheld for taxes	(107)	-	(75)	-	-	(75)
Stock-based compensation	-	-	600	-	-	600
Net loss	-	-	-	(50,340)	-	(50,340)
Other comprehensive income	-	-	-	-	1,309	1,309
Balance at March 31, 2025	44,214	$442	$237,104	$(208,350)	$(14,361)	$14,835
Accumulated
Number · Additional · Other · Total
	of Shares	Common	Paid-in	Accumulated	Comprehensive	Stockholders’
	Issued	Stock	Capital	Deficit	Loss	Equity
Balance at December 31, 2023	43,395	$434	$232,435	$(145,605)	$(14,190)	$73,074
Stock option exercises	4	-	15	-	-	15
Vesting of restricted stock units	34	-	-	-	-	-
Shares withheld for taxes	(12)	-	(47)	-	-	(47)
Stock-based compensation	-	-	1,048	-	-	1,048
Net loss	-	-	-	(4,694)	-	(4,694)
Other comprehensive loss	-	-	-	-	(584)	(584)
Balance at March 31, 2024	43,421	$434	$233,451	$(150,299)	$(14,774)	$68,812

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.